Simeon George

Dr. George is CEO of S.R. One. He was formerly a consultant at Bain & Co. and an associate in the healthcare investment banking group at Goldman Sachs. Dr. George is a co-founder and board member of Nkarta and also currently serves on the boards of Bird Rock Bio, CRISPR Therapeutics (CRSP), eFFECTOR Therapeutics, Principia Biopharma (PRNB) and Turning Point Therapeutics (TPTX). He previously served of the boards of Progyny (PGNY), HTG Molecular (HTGM), Genocea Biosciences (GNCA) and Semprus (acquired by Teleflex). Dr. George received a B.A. in neuroscience from Johns Hopkins University, where he graduated Phi Beta Kappa. He received an M.D. from the University of Pennsylvania School of Medicine and a MBA (Mayer Scholar) from the Wharton School at the University of Pennsylvania.